TITLE:
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

CONDITION:
Pneumonia, Pneumocystis Carinii

INTERVENTION:
Atovaquone

SUMMARY:

      To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis
      carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim /
      sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria

        Patients must have the following:

          -  Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP).

          -  Dose-limiting intolerance to TMP / SMX and parenteral pentamidine.

          -  Willingness and ability to give informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Excluded:

          -  Patients with a history of intolerance to 566C80. Patients with the following prior
             conditions are excluded: History of serious dose-limiting adverse experience during
             previous 566C80 therapy, thought to be attributable to the drug.

        Required:

          -  Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.
      
